3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
8
Active not recruiting
6
Recruiting
3
Unknown
2
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Gastrointestinal
4
Thoracic
3
Breast
3
Sarcoma
2
Gynecologic
2
Other neoplasm
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Endocrine
1
Conditions
Leukemia, B-Cell
1
Interventions
Cyclophosphamide
122
Cytarabine
112
fludarabine
91
fludarabine phosphate
80
Rituximab
75
Azacitidine
75
venetoclax
55
Methotrexate
52
Filgrastim
48
Whole-Body Irradiation
45
Busulfan
45
Tacrolimus
35
Etoposide
35
Mycophenolic Acid
34
Lenalidomide
32
Imatinib Mesylate
32
Antilymphocyte Serum
32
Granulocyte Colony-Stimulating Factor
31
Decitabine
31
Peripheral Blood Stem Cell Transplantation
29
Dexamethasone
29
Cyclosporine
29
Vincristine
26
Melphalan
26
Clofarabine
25
Alemtuzumab
25
Mitoxantrone
24
Stem Cell Transplantation
22
Radiotherapy
22
Dasatinib
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Observation
×
Other hematologic neoplasm
×
Clear all
NCT01039376
2019-07-30
PROLONG
Novartis
Phase 3
Terminated
480 enrolled
30 charts